3 British AI Stocks With Revenue Growth Up To 14%

UK consumer demand is gradually rebounding, even as inflation and energy costs continue to shape household budgets. That mix of pressure and recovery is pushing healthcare providers to look harder at Artificial Intelligence tools that can cut waste and support better care. For investors, that creates a focused way to gain exposure to AI in medicine. This article highlights three Transformative AI Healthcare stocks from our screener.

The stocks below are just a starting sample, and the full screen has surfaced 5 more AI healthcare companies with equally compelling stories that are not covered here. If you want to identify and analyze the highest conviction opportunities in this theme, go straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Haleon is a global consumer healthcare company behind brands like Sensodyne, Centrum, Voltaren and Advil. It is now working with Microsoft to apply AI across product development, marketing personalization and supply chain decisions. The business is broad based, with revenue of about £3.8b from North America, £4.7b from Europe, the Middle East, Africa and Latin America, and £2.6b from Asia Pacific. The company is sizeable, with a market cap of roughly £31.1b.

Investors looking at AI in healthcare may focus on Haleon because its Microsoft partnership aims to use AI to support new product ideas, sharpen consumer targeting and improve supply chain planning, all on top of an existing portfolio of everyday health brands. There are clear risks, including regulatory pressure on over the counter products, consumer shifts toward more natural remedies and a meaningful debt load, so execution on AI and operational efficiency is important. The company’s AI initiatives and India expansion are key factors for margins and business resilience, particularly given the current mixed earnings picture and cautious analyst narratives.

Haleon’s AI push with Microsoft builds on everyday health brands that consumers already know. However, the real story lies in how margins, debt and growth ambitions intersect in the analysis report for Haleon

IXICO (AIM:IXI)

IXICO is a London based medical data analytics company that runs an AI enabled neuroimaging platform used to read brain scans and extract imaging biomarkers for neurological clinical trials and diagnostics. It generates about £7.3 million in revenue from Medical Labs & Research services such as imaging CRO support, biomarker extraction and data management across conditions like Alzheimer’s, Huntington’s, MS and Parkinson’s disease. The company is small, with a market cap of roughly £16 million.

IXICO gives you pure play exposure to AI in brain imaging, where better biomarkers can make or break neurology drug trials. The company’s IXICO platform and recent collaborations with the Paris Brain Institute and leading neurologists indicate growing technical depth and potential demand for its AI driven readouts. At the same time, IXICO is still loss making, relies on higher risk external funding and has seen board turnover, so the path to profitable scale is not guaranteed. For investors who can tolerate these risks, the combination of focused AI capability in neurodegeneration and a modest valuation base may warrant a closer look at the numbers and contract pipeline.

IXICO’s AI neuroimaging story is still small in scale. Yet the real question is how that focus, funding risk and contract pipeline fit together in the 1 key reward and 3 important warning signs (2 are major!)

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical company that develops and sells prescription drugs across oncology, cardiovascular and metabolic disease, respiratory and immunology, vaccines and rare diseases, while partnering with Tempus and Pathos to apply AI across imaging, genomics and clinical data in cancer. The company generates about $61.4b in revenue from pharmaceuticals and has a market cap of roughly £186.2b. That makes its AI oncology work a focused line inside a much larger and diversified drug portfolio.

Investors looking at AstraZeneca are weighing a large, diversified pharma business that is integrating AI into oncology alongside the usual patent and pricing risks in the sector. The Tempus and Pathos collaboration aims to build one of the largest multimodal AI models in cancer, which could sharpen diagnosis, guide treatment selection and feed value back into an already deep oncology pipeline. At the same time, AstraZeneca still leans on a handful of blockbuster drugs and continues to spend heavily on R&D, so execution on new launches and AI programs matters. A key consideration is how much that AI capability and late stage pipeline may help address competition, price pressure and a full R&D bill before the market fully reflects it.

AstraZeneca’s accelerating AI push in oncology is easy to overlook inside a $61.4b pharma giant, yet the real signal sits in the late stage pipeline and how that interacts with the analyst forecasts for AstraZeneca

Seeking Fresh Alternatives Beyond Healthcare AI?

Some of the most widely discussed ideas may move early, drawing attention only after momentum has already built. Review these shortlists while they are still emerging and decide whether any fit your strategy.

• Explore potential income-focused opportunities that may be less widely followed for now by reviewing our curated list of 5 dividend fortresses.
• Identify companies involved in automation and manufacturing that may be gaining traction by checking the hand picked group of 36 robotics and automation stocks.
• Evaluate businesses connected to computing infrastructure that supports AI by assessing a focused selection of 55 AI infrastructure stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com